Copper Radiopharmaceuticals for Molecular Imaging of Alzheimer's Disease. The expected outcome of this research is to develop molecular agents to allow non-invasive diagnostic imaging of senile plaques associated with the onset of Alzheimer's disease. This will contribute to a better understanding of the disease, assist in early diagnosis and help assess new intervention strategies. Alzheimer's disease is the most common form of dementia and affects over 160,000 Australians. The imaging agent ma ....Copper Radiopharmaceuticals for Molecular Imaging of Alzheimer's Disease. The expected outcome of this research is to develop molecular agents to allow non-invasive diagnostic imaging of senile plaques associated with the onset of Alzheimer's disease. This will contribute to a better understanding of the disease, assist in early diagnosis and help assess new intervention strategies. Alzheimer's disease is the most common form of dementia and affects over 160,000 Australians. The imaging agent market is a niche biotechnology industry in which Australia already has an international presence. The proposed research will lead to innovations to ensure Australia remains internationally competitive in this area. This research has potential social and economic benefits for the nation.Read moreRead less